A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
Start Date
9/29/2025
Completion Date
7/1/2032
Summary
The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.
Eligibility Criteria
Age Range: 8 years to 55 years
Interventions
AAVB-039
Conditions
Locations
Associated Retina Consultants
Phoenix, Arizona 85020
United States
Children's Hospital Los Angeles
Los Angeles, California 90027
United States
Retina Vitreous Associates Medical Group
Los Angeles, California 90211
United States
University of Florida Health Science Center
Jacksonville, Florida 32209
United States
Mayo Clinic
Rochester, Minnesota 55905
United States
Retina Consultants of Texas
Bellaire, Texas 77401
United States
Retina Foundation of the Southwest
Dallas, Texas 75231
United States
University of Utah
Salt Lake City, Utah 84112
United States
Oslo University Hospital
Oslo, Kirkeveien 166
Norway
Moorfields Eye Hospital NHS Foundation Trust
London, England EC1V 2PD
United Kingdom
The Retina Clinic
London, England W1G 9AY
United Kingdom